Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN Phase I clinical trial.

Journal of neurosurgery. Spine

Volumn 17, Issue 1 Suppl, 2012, Pages 151-156

  Fehlings, Michael G ^a   Wilson, Jefferson R ^b   Frankowski, Ralph F ^b   Toups, Elizabeth G ^b   Aarabi, Bizhan ^b   Harrop, James S ^b   Shaffrey, Christopher I ^b   Harkema, Susan J ^b   Guest, James D ^b   Tator, Charles H ^b   Burau, Keith D ^b   Johnson, Michele W ^b   Grossman, Robert G ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPROTECTIVE AGENT; RILUZOLE;

ARTICLE; HUMAN; METHODOLOGY; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; SPINAL CORD INJURY;

HUMANS; NEUROPROTECTIVE AGENTS; RESEARCH DESIGN; RILUZOLE; SPINAL CORD INJURIES;

MLCS; MLOWN;

EID: 84872202507     PISSN: None     EISSN: 15475646     Source Type: Journal    
DOI: 10.3171/2012.4.aospine1259     Document Type: Article

References (0)